These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32588918)

  • 21. Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative.
    Upadhyay VA; Geisler BP; Sun L; Uhl L; Kaufman RM; Stowell C; Makar RS; Bendapudi PK
    Br J Haematol; 2019 Aug; 186(3):490-498. PubMed ID: 31131442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive Value of Schistocytes in Recurrence of Acquired Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency at Discontinuation of Daily Therapeutic Plasma Exchange.
    Peedin AR; Park YA; Mazepa MA; Rollins-Raval MA; Brecher ME; Raval JS
    Ther Apher Dial; 2018 Dec; 22(6):662-665. PubMed ID: 30178615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of PLASMIC Score in Risk Prediction of Thrombotic Thrombocytopenic Purpura: Real-World Experience From a Tertiary Medical Center in Taiwan.
    Lee CH; Huang YC; Li SS; Hsu YT; Chen YP; Chen TY
    Front Med (Lausanne); 2022; 9():893273. PubMed ID: 35615090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange.
    Bentley MJ; Lehman CM; Blaylock RC; Wilson AR; Rodgers GM
    Transfusion; 2010 Aug; 50(8):1654-64. PubMed ID: 20412532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validating lactate dehydrogenase (LDH) as a component of the PLASMIC predictive tool (PLASMIC-LDH).
    Liam CCK; Tiao JY; Yap YY; Lee YL; Sathar J; McRae S; Davis A; Curnow J; Bird R; Choi P; Angchaisuksiri P; Tien SL; Lam JCM; Oh D; Kim JS; Yoon SS; Wong RS; Lauren C; Merriman EG; Enjeti A; Smith M; Baker RI
    Blood Res; 2023 Mar; 58(1):36-41. PubMed ID: 36632683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombotic thrombocytopenic purpura: The role of ADAMTS13.
    Rogers HJ; Allen C; Lichtin AE
    Cleve Clin J Med; 2016 Aug; 83(8):597-603. PubMed ID: 27505881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of the ADAMTS13 activity assay improved the accuracy and efficiency of the diagnosis and treatment of suspected acquired thrombotic thrombocytopenic purpura.
    Barrows BD; Teruya J
    Arch Pathol Lab Med; 2014 Apr; 138(4):546-9. PubMed ID: 24678685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of ADAMTS13 activity and inhibitor in the postmortem diagnosis of thrombotic thrombocytopenic purpura.
    Dwyre DM; Dursteler B; Nashelsky M; Friedman KD; Raife TJ
    J Clin Apher; 2009; 24(3):106-10. PubMed ID: 19253359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
    Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
    Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasmic score applicability for the diagnosis of thrombotic microangiopathy associated with ADAMTS13-acquired deficiency in a developing country.
    Oliveira DS; Lima TG; Benevides FLN; Barbosa SAT; Oliveira MA; Boris NP; Silva HF
    Hematol Transfus Cell Ther; 2019; 41(2):119-124. PubMed ID: 31079658
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Kim Y; Ahn A; Lee JM; Kim M; Lee HK; Kim H
    Ann Clin Lab Sci; 2024 Mar; 54(2):265-269. PubMed ID: 38802156
    [No Abstract]   [Full Text] [Related]  

  • 32. [The diagnostic value of PLASMIC score in the discrimination between thrombotic thrombocytopenic purpura and disseminated intravascular coagulation].
    Yin J; Yu ZQ; Kong DQ; Wang ZY; Jin J; Wang J; Wang XM; Su J; Zhang W; Ruan CG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Oct; 39(10):812-816. PubMed ID: 30369201
    [No Abstract]   [Full Text] [Related]  

  • 33. Atypical presentations of thrombotic thrombocytopenic purpura: a diagnostic role for ADAMTS13.
    Kalish Y; Rottenstreich A; Rund D; Hochberg-Klein S
    J Thromb Thrombolysis; 2016 Aug; 42(2):155-60. PubMed ID: 26867546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura.
    Allen C; Ito S; Butt A; Purcell A; Richmond R; Tormey CA; Krumholz HM; Cuker A; Goshua G
    Blood Adv; 2024 May; 8(9):2279-2289. PubMed ID: 38502197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seasonal distribution of severe ADAMTS13 deficient idiopathic thrombotic thrombocytopenic purpura.
    Raval JS; Harm SK; Rollins-Raval MA; Kiss JE
    J Clin Apher; 2014 Apr; 29(2):113-9. PubMed ID: 24123112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absolute immature platelet count dynamics in diagnosing and monitoring the clinical course of thrombotic thrombocytopenic purpura.
    Hong H; Xiao W; Stempak LM; Sandhaus LM; Maitta RW
    Transfusion; 2015 Apr; 55(4):756-65. PubMed ID: 25370931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. von Willebrand factor and its cleaving protease ADAMTS13 balance in coronary artery vessels: Lessons learned from thrombotic thrombocytopenic purpura. A narrative review.
    Morici N; Cantoni S; Panzeri F; Sacco A; Rusconi C; Stucchi M; Oliva F; Cattaneo M
    Thromb Res; 2017 Jul; 155():78-85. PubMed ID: 28521259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
    Joly BS; Stepanian A; Leblanc T; Hajage D; Chambost H; Harambat J; Fouyssac F; Guigonis V; Leverger G; Ulinski T; Kwon T; Loirat C; Coppo P; Veyradier A;
    Lancet Haematol; 2016 Nov; 3(11):e537-e546. PubMed ID: 27720178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and validation of a multivariable prediction rule for detecting a severe acquired ADAMTS13 activity deficiency in patients with thrombotic microangiopathies.
    Nieto JM; De La Fuente-Gonzalo F; González FA; Villegas A; Martínez R; Fuentes ME; Ropero P
    Clin Chem Lab Med; 2018 Jan; 56(2):294-302. PubMed ID: 28796639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid ADAMTS13 availability impacts treatment for microangiopathic hemolytic anemia and thrombocytopenia.
    Martin IW; Katus MC; Martin CL; Szczepiorkowski ZM; Gorham JD; Dunbar NM
    J Clin Apher; 2016 Oct; 31(5):419-22. PubMed ID: 26332753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.